HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

Source: FDA

Why This Matters

Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.

Supporting Context

Therapeutic area
Respiratory · Bronchodilator
Sub-indication
General

Related signal: Lupin Inc. Submits ANDA for Revefenacin to FDA

Source

View source document

Related Signal

Open signal — Lupin Inc. Submits ANDA for Revefenacin to FDA
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.